Arbutus Biopharma Corporation

(NASDAQ:ABUS)

Latest On Arbutus Biopharma Corporation (ABUS):

Date/Time Type Description Signal Details
2023-05-18 02:45 ESTNewsArbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023N/A
2023-05-04 21:46 ESTNewsArbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:45 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67MN/A
2023-04-25 14:16 ESTNewsArbutus sheds 18% after FDA clinical hold on antiviralN/A
2023-04-12 00:01 ESTNewsModerna wins appeals court ruling in Arbutus COVID vaccine patent disputeN/A
2023-04-05 02:46 ESTNewsPfizer, BioNTech dip as Arbutus charges violation of COVID vaccine patentsN/A
2023-03-02 12:31 ESTNewsArbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88MN/A
2023-03-02 12:30 ESTNewsArbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 22:16 ESTNewsArbutus Biopharma FY 2022 Earnings PreviewN/A
2023-02-23 11:16 ESTNewsArbutus Biopharma Corp.: Long Road Ahead For HBV CureN/A
2022-11-09 19:33 ESTNewsArbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23MN/A
2022-11-09 19:32 ESTNewsArbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 19:32 ESTNewsArbutus trades higher as Q3 net loss narrows, revenue grows on license dealN/A
2022-11-07 14:15 ESTNewsArbutus Biopharma (ABUS) presents at AASLD 2022 - SlideshowN/A
2022-11-03 05:01 ESTNewsArbutus gains after court denies Moderna motion to dismiss Covid-19 royalties caseN/A
2022-09-12 13:02 ESTNewsArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'N/A
2022-08-30 16:31 ESTNewsArbutus stock rises on US patent linked to hepatitis B therapy AB-729N/A
2022-08-04 22:47 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47MN/A
2022-08-04 22:46 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 16:46 ESTNewsArbutus Biopharma Q2 2022 Earnings PreviewN/A
2022-07-20 18:00 ESTNewsArbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trialN/A
2022-06-30 05:46 ESTNewsArbutus: 2 Key Catalysts To Look Forward To After EASL Data ReleaseN/A
2022-06-06 15:46 ESTNewsArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentN/A
2022-05-05 20:18 ESTNewsArbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16MN/A
2022-05-05 20:16 ESTNewsArbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 21:31 ESTNewsArbutus Biopharma Q1 2022 Earnings PreviewN/A
2022-03-19 19:34 ESTNewsArbutus sued to avoid patent dispute over Pfizer/BioNTech COVID-19 shotN/A
2022-03-14 23:02 ESTNewsArbutus price target raised at H.C. Wainwright on upcoming data readoutsN/A
2022-03-08 08:32 ESTNewsArbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestN/A
2022-03-04 00:32 ESTNewsArbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35MN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 12:45 ESTNewsArbutus Biopharma Q4 2021 Earnings PreviewN/A
2022-03-01 02:17 ESTNewsModerna hit by lawsuit as Arbutus, Genevant seek damages for use of COVID-19 vaccine patentsN/A
2022-01-24 16:17 ESTNewsArbutus Biopharma outlines milestones for 2022N/A
2021-12-22 11:31 ESTNewsRoivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy ArbutusN/A
2021-12-17 17:31 ESTNewsArbutus Biopharma: How Will Patent Win Impact Stock Outlook?N/A
2021-12-13 14:32 ESTNewsArbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%N/A
2021-12-08 01:33 ESTNewsArbutus identifies molecular targets for COVID-19 treatmentN/A
2021-12-01 16:46 ESTNewsModerna loses patent fight against Arbutus related to vaccines; Arbutus up 40%N/A
2021-12-01 16:46 ESTNewsArbutus chronic hepatitis B virus treatment shows antiviral activity in early-stage trialN/A
2021-12-01 16:46 ESTNewsRoivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%N/A
2021-11-20 03:16 ESTNewsArbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive InvestmentN/A
2021-11-19 06:32 ESTNewsAlnylam, Arrowhead gain on Novo bid to acquire DicernaN/A
2021-11-05 00:18 ESTNewsArbutus Biopharma EPS in-line, beats on revenueN/A
2021-11-05 00:16 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 03:02 ESTNewsArbutus Biopharma Q3 2021 Earnings PreviewN/A
2021-10-09 16:30 ESTNewsA look at the biopharmas developing new treatments for liver diseasesN/A
2021-10-07 03:30 ESTNewsModerna slips ahead of legal battle to invalidate COVID-19 vaccine patentsN/A
2021-09-22 20:29 ESTNewsArbutus Biopharma (ABUS) Investor Presentation - SlideshowN/A

About Arbutus Biopharma Corporation (ABUS):

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Quotes by TradingView

See Advanced Chart

General

  • Name Arbutus Biopharma Corporation
  • Symbol ABUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 76
  • Last Split Factor1:5
  • Last Split Date2010-11-04
  • Fiscal Year EndDecember
  • IPO Date2015-08-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arbutusbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.69
  • Price/Book (Most Recent Quarter) 2.44
  • Enterprise Value Revenue 56.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.86
  • Next Year EPS Estimate -$0.67
  • Next Quarter EPS Estimate -$0.23
  • Operating Margin -828%
  • Return on Assets -30%
  • Return on Equity -73%
  • Revenue 6.91 million
  • Earnings Per Share -$1.79
  • Revenue Per Share $0.09
  • Gross Profit -40567000
  • Quarterly Earnings Growth 47.5%
View More

Highlights

  • Market Capitalization 349.26 million
  • EBITDA -71643000
  • PE Ratio -9.48
  • Analyst Target Price $6.11
  • Book Value Per Share $1.23
View More

Share Statistics

  • Shares Outstanding 95.58 million
  • Shares Float 69.81 million
  • % Held by Insiders 2123%
  • % Held by Institutions 30.96%
  • Shares Short 3.27 million
  • Shares Short Prior Month 2.55 million
  • Short Ratio 0.94
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 3.05
  • 52 Week High $6.48
  • 52 Week Low $0.88
  • 50 Day Moving Average 3.96
  • 200 Day Moving Average 3.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arbutus Biopharma Corporation (ABUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arbutus Biopharma Corporation (ABUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$2.39 million-$0.23-$0.22-2.74%
2020-09-302020-11-05$N/A-$0.27-$0.22-26.07%
2020-06-302020-08-07$N/A-$0.25-$0.24-1.59%
2020-03-312020-05-11$1.49 million-$0.25-$0.3120.71%
2019-12-312020-03-05$1.62 million-$0.46-$0.36-26.6%
2019-09-302019-11-06$3.06 million-$1.50-$0.34-346.17%
2019-06-302019-08-05$653000-$0.46-$0.38-22.19%
2019-03-312019-05-06$679000-$0.47-$0.32-46.41%
2018-12-312019-03-07$1.68 million-$0.37-$0.406.98%
2018-09-302018-11-07$1.59 million-$0.49-$0.41-19.75%
2018-06-302018-08-02$1.24 million$0.01-$0.39102.54%
2018-03-312018-05-03$1.44 million-$0.36-$0.4010.76%
2017-12-312018-03-14$2.53 million-$0.67-$0.38-73.97%
2017-09-302017-11-02$6.89 million-$0.21-$0.3540.78%
2017-06-302017-08-03$1.04 million-$0.33-$0.4221.27%
2017-03-312017-05-04$235000-$0.34-$0.30-12.68%
2016-12-312017-03-21$-195000-$4.08-$0.40-932.74%
2016-09-302016-11-03$774000-$0.37-$0.5025.5%
2016-06-302016-08-04$309000-$2.47-$0.39-528.02%
2016-03-312016-05-04$603000-$0.31-$0.3716.46%
2015-12-312016-03-09$15.26 million-$0.10-$0.3974.17%
2015-09-302015-11-05$4.07 million-$0.12-$0.2958.62%
2015-06-302015-08-07$869000-$0.27-$0.296.9%
2015-03-312015-05-06$4.68 million-$0.40-$0.36-11.11%
2014-12-312015-03-12$4.35 million-$0.27-$0.283.57%
2014-09-302014-11-06$4.36 million-$0.39-$0.31-25.81%
2014-06-302014-08-13$1.81 million-$0.28-$0.25-12%
2014-03-312014-05-14$4.43 million-$0.91$0.16-668.75%
2013-12-312014-03-06$7.51 million-$0.10$0.06-266.67%
2013-09-302013-11-13$2.96 million-$0.42-$0.21-100%
2013-06-302013-08-12$2.79 million-$0.21
2013-03-312013-05-14$2.16 million-$0.18
2012-12-312013-03-27$3.91 million$2.70
2012-09-302012-11-13$3.1 million-$0.25
2012-06-302012-08-14$3.56 million-$0.14-$0.1612.5%
2012-03-312012-05-15$3.6 million-$0.25-$0.17-47.06%
2011-12-312012-03-27$3.66 million-$0.15
2011-09-302011-11-08$3.96 million-$0.12-$0.3060%
2011-06-302011-08-11$4.58 million-$0.33-$0.30-10%
2011-03-312011-05-10$4.48 million-$0.30-$0.3616.67%
2010-12-312011-03-30$6.21 million-$0.20-$0.2520%
2010-09-302010-11-15$4.34 million-$1.09-$0.20-445%
2010-06-302010-08-12$2.18 million-$0.40-$0.35-14.29%
2009-12-312010-03-17$4.27 million-$0.25-$0.3016.67%
2009-06-302009-08-12$3.25 million-$0.20-$0.15-33.33%
2009-03-312009-05-13$2.28 million-$0.20-$0.2520%
2008-12-312009-03-24$2.53 million-$0.35-$0.5030%
2007-12-312008-03-30$4.22 million$0.10$0.05100%
2007-09-302007-11-14$5.76 million$0.30$0.45-33.33%
2007-06-302007-08-08$2.82 million-$1.05-$0.30-250%

Arbutus Biopharma Corporation (ABUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arbutus Biopharma Corporation (ABUS) Chart:

Arbutus Biopharma Corporation (ABUS) News:

Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arbutus Biopharma Corporation (ABUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-2110CALL0 0701.67TRUE00
2025-03-211.50CALL0 0281.86TRUE00
2025-03-2121.27CALL0 111709.45TRUE00
2025-03-212.50.9CALL0 27809.02TRUE00
2025-03-2130.5CALL1551 162555.13TRUE00
2025-03-213.50.25CALL46 183770.29FALSE0.250
2025-03-2140.1CALL10 62371.25FALSE00
2025-03-214.50.05CALL10 25979.09FALSE0.050
2025-03-2150.05CALL0 524130.94FALSE00
2025-03-215.50CALL0 0229.09FALSE00
2025-03-2160.08CALL0 331167.45FALSE00
2025-03-2170.15CALL0 6215.77FALSE00
2025-03-2110PUT0 0625.81FALSE00
2025-03-211.50PUT0 0437.56FALSE00
2025-03-2120PUT0 0320.26FALSE00
2025-03-212.50PUT0 0313.31FALSE00
2025-03-2130.11PUT20 6777.44FALSE0.110
2025-03-213.50.3PUT0 134638.2TRUE00
2025-03-2140.8PUT0 815101.03TRUE00
2025-03-214.51.36PUT0 70146.69TRUE00
2025-03-2150PUT0 0248.12TRUE00
2025-03-215.50PUT0 0161.32TRUE00
2025-03-2160PUT0 0196.77TRUE00
2025-03-2170PUT0 0275.73TRUE00
2025-04-1710CALL0 0305.83TRUE00
2025-04-1720CALL0 0352.62TRUE00
2025-04-1730CALL0 0108.46TRUE00
2025-04-1740CALL0 071.67FALSE00
2025-04-1750CALL0 0100.02FALSE00
2025-04-1760CALL0 0383.69FALSE00
2025-04-1710PUT0 00FALSE00
2025-04-1720PUT0 0641.39FALSE00
2025-04-1730PUT0 060.04FALSE00
2025-04-1740PUT0 0112.52TRUE00
2025-04-1750PUT0 0115.38TRUE00
2025-04-1760PUT0 0125.18TRUE00
2025-06-2010CALL0 0392.51TRUE00
2025-06-2021.34CALL0 35138.37TRUE00
2025-06-2030.75CALL675 253664.71TRUE0.750
2025-06-2040.3CALL800 105961.14FALSE0.040.15
2025-06-2050.1CALL22 32558.66FALSE-0.05-0.33
2025-06-2060.25CALL0 52124.42FALSE00
2025-06-2070.15CALL0 30136.84FALSE00
2025-06-2010PUT0 0310.04FALSE00
2025-06-2020PUT0 0159.3FALSE00
2025-06-2030.3PUT0 251057.92FALSE00
2025-06-2040.81PUT0 16559.55TRUE00
2025-06-2050PUT0 065.72TRUE00
2025-06-2060PUT0 0138.65TRUE00
2025-06-2070PUT0 0214.4TRUE00
2025-08-150.50CALL0 0312.48TRUE00
2025-08-1510CALL0 0323.3TRUE00
2025-08-151.50CALL0 0271.13TRUE00
2025-08-1520CALL0 0236.46TRUE00
2025-08-152.51.1CALL0 8494.83TRUE00
2025-08-1530.84CALL0 104231.06TRUE00
2025-08-153.50.57CALL0 2360.23FALSE00
2025-08-1540.35CALL0 5253.3FALSE00
2025-08-154.50.3CALL0 60257.35FALSE00
2025-08-1550.4CALL0 35551.64FALSE00
2025-08-155.50CALL0 076.64FALSE00
2025-08-1560.18CALL0 10269.38FALSE00
2025-08-1570.3CALL0 289.94FALSE00
2025-08-150.50PUT0 0472.02FALSE00
2025-08-1510PUT0 0257.22FALSE00
2025-08-151.50PUT0 0180.27FALSE00
2025-08-1520PUT0 088.05FALSE00
2025-08-152.50.15PUT0 674FALSE00
2025-08-1530.4PUT0 2248.66FALSE00
2025-08-153.50.65PUT0 23539.45TRUE00
2025-08-1541.08PUT0 156.04TRUE00
2025-08-154.50PUT0 058.81TRUE00
2025-08-1550PUT0 0103.57TRUE00
2025-08-155.50PUT0 065.44TRUE00
2025-08-1560PUT0 0178.19TRUE00
2025-08-1570PUT0 0131.74TRUE00
2025-09-1910CALL0 0188.74TRUE00
2025-09-1920CALL0 0215.47TRUE00
2025-09-1930CALL0 0274.46TRUE00
2025-09-1940CALL0 0251.58FALSE00
2025-09-1950.25CALL0 1256.3FALSE00
2025-09-1960CALL0 073.64FALSE00
2025-09-1970CALL0 0269.2FALSE00
2025-09-1910PUT0 0235.61FALSE00
2025-09-1920PUT0 085.78FALSE00
2025-09-1930PUT0 056.41FALSE00
2025-09-1940PUT0 061.71TRUE00
2025-09-1950PUT0 0107.82TRUE00
2025-09-1960PUT0 084.34TRUE00
2025-09-1970PUT0 0161.14TRUE00
2025-10-1710CALL0 0176.75TRUE00
2025-10-1720CALL0 0220.34TRUE00
2025-10-1730CALL0 0279.74TRUE00
2025-10-1740CALL0 0253.44FALSE00
2025-10-1750CALL0 0253.23FALSE00
2025-10-1760.3CALL0 277.04FALSE00
2025-10-1770CALL0 0264.38FALSE00
2025-10-1780CALL0 0273.16FALSE00
2025-10-1710PUT0 00FALSE00
2025-10-1720PUT0 089.8FALSE00
2025-10-1730PUT0 058.71FALSE00
2025-10-1741.1PUT0 1469.93TRUE00
2025-10-1750PUT0 071.97TRUE00
2025-10-1760PUT0 074.69TRUE00
2025-10-1770PUT0 0161.7TRUE00
2025-10-1780PUT0 0186.5TRUE00
2026-01-160.50CALL0 0136.7TRUE00
2026-01-1612.55CALL0 577.4TRUE00
2026-01-161.50CALL0 0157.65TRUE00
2026-01-1621.8CALL10 15086.26TRUE1.80
2026-01-162.52.2CALL0 4205TRUE00
2026-01-1631.06CALL0 13287.52TRUE00
2026-01-163.50.75CALL2 135110.42FALSE-0.15-0.17
2026-01-1640.65CALL0 2571.2FALSE00
2026-01-164.51CALL0 51244.89FALSE00
2026-01-1650.5CALL0 125193.74FALSE00
2026-01-165.50.55CALL0 22256.64FALSE00
2026-01-1670CALL0 0263.56FALSE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610PUT0 00FALSE00
2026-01-161.50PUT0 085.15FALSE00
2026-01-1620PUT0 065.7FALSE00
2026-01-162.50PUT0 064.25FALSE00
2026-01-1630.65PUT0 357.86FALSE00
2026-01-163.50PUT0 046.63TRUE00
2026-01-1641.06PUT0 1531.54TRUE00
2026-01-164.51.46PUT0 10089.69TRUE00
2026-01-1650PUT0 087.21TRUE00
2026-01-165.50PUT0 087.2TRUE00
2026-01-1670PUT0 0101.58TRUE00
2027-01-152.52.52CALL0 3139.15TRUE00
2027-01-1530CALL0 0148.63TRUE00
2027-01-153.51.5CALL0 4199.25FALSE00
2027-01-1541.13CALL0 5188.53FALSE00
2027-01-154.50CALL0 043.19FALSE00
2027-01-1550.77CALL0 15171.52FALSE00
2027-01-155.50.8CALL0 18064.69FALSE00
2027-01-1570.55CALL0 8258.47FALSE00
2027-01-152.50PUT0 066.35FALSE00
2027-01-1530PUT0 075.5FALSE00
2027-01-153.50PUT0 052.39TRUE00
2027-01-1540PUT0 046.11TRUE00
2027-01-154.50PUT0 040.61TRUE00
2027-01-1550PUT0 0113.96TRUE00
2027-01-155.50PUT0 0107.68TRUE00
2027-01-1570PUT0 088.31TRUE00

Latest ABUS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST400$2.39
Jun 13, 2022 7:59 PM EST200$2.39
Jun 13, 2022 7:59 PM EST1000$2.39
Jun 13, 2022 7:59 PM EST200$2.385
Jun 13, 2022 7:59 PM EST17$2.385

Arbutus Biopharma Corporation (ABUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1447028/000000000019016815/0000000000-19-016815-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000089542120000423/0000895421-20-000423-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000089924319019548/0000899243-19-019548-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000004/0000903423-19-000004-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000012/0000903423-19-000012-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000288/0000903423-19-000288-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000298/0000903423-19-000298-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000299/0000903423-19-000299-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583619000122/0000935836-19-000122-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583620000133/0000935836-20-000133-index.htm
2018-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000104746918007755/0001047469-18-007755-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746919002498/0001047469-19-002498-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746920002560/0001047469-20-002560-index.htm
2018-12-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074106/0001104659-18-074106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074112/0001104659-18-074112-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919006779/0001104659-19-006779-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919008025/0001104659-19-008025-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919023074/0001104659-19-023074-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919030387/0001104659-19-030387-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040421/0001104659-19-040421-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040422/0001104659-19-040422-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040589/0001104659-19-040589-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040594/0001104659-19-040594-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040598/0001104659-19-040598-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040934/0001104659-19-040934-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919045102/0001104659-19-045102-index.htm
2019-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919059987/0001104659-19-059987-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919070902/0001104659-19-070902-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465920020447/0001104659-20-020447-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000110465920100169/0001104659-20-100169-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001084/0001123292-18-001084-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001085/0001123292-18-001085-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001115/0001123292-18-001115-index.htm
2018-12-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001125/0001123292-18-001125-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/0001123292-19-000431-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000432/0001123292-19-000432-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000435/0001123292-19-000435-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000436/0001123292-19-000436-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000437/0001123292-19-000437-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000438/0001123292-19-000438-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000910/0001123292-19-000910-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000911/0001123292-19-000911-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034587/0001144204-19-034587-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034595/0001144204-19-034595-index.htm
2018-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006281/0001171843-18-006281-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006907/0001171843-18-006907-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007089/0001171843-18-007089-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007727/0001171843-18-007727-index.htm
2018-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318008152/0001171843-18-008152-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319001586/0001171843-19-001586-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319002996/0001171843-19-002996-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004042/0001171843-19-004042-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004412/0001171843-19-004412-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319005142/0001171843-19-005142-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184320007636/0001171843-20-007636-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193243/0001193125-19-193243-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193262/0001193125-19-193262-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000120919119041996/0001209191-19-041996-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000006/0001447028-19-000006-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000010/0001447028-19-000010-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000015/0001447028-19-000015-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000018/0001447028-19-000018-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/0001447028-19-000025-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000031/0001447028-19-000031-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000049/0001447028-19-000049-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000050/0001447028-19-000050-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000051/0001447028-19-000051-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000052/0001447028-19-000052-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000053/0001447028-19-000053-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/0001447028-19-000054-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000055/0001447028-19-000055-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000056/0001447028-19-000056-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000057/0001447028-19-000057-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000060/0001447028-19-000060-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000064/0001447028-19-000064-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000069/0001447028-19-000069-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000071/0001447028-19-000071-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000144702819000078/0001447028-19-000078-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000081/0001447028-19-000081-index.htm
2020-01-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000004/0001447028-20-000004-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000006/0001447028-20-000006-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000009/0001447028-20-000009-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000024/0001447028-20-000024-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000025/0001447028-20-000025-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000026/0001447028-20-000026-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/0001447028-20-000027-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000028/0001447028-20-000028-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000029/0001447028-20-000029-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000030/0001447028-20-000030-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000031/0001447028-20-000031-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000035/0001447028-20-000035-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000038/0001447028-20-000038-index.htm
2020-03-0610-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000041/0001447028-20-000041-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000043/0001447028-20-000043-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000046/0001447028-20-000046-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000049/0001447028-20-000049-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000052/0001447028-20-000052-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/0001447028-20-000063-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000064/0001447028-20-000064-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000065/0001447028-20-000065-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000066/0001447028-20-000066-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000067/0001447028-20-000067-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000068/0001447028-20-000068-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000069/0001447028-20-000069-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000071/0001447028-20-000071-index.htm
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000078/0001447028-20-000078-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000100/0001447028-20-000100-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/0001447028-20-000118-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000121/0001447028-20-000121-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000124/0001447028-20-000124-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000126/0001447028-20-000126-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000129/0001447028-20-000129-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000135/0001447028-20-000135-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000140/0001447028-20-000140-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000143/0001447028-20-000143-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000144/0001447028-20-000144-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000150/0001447028-20-000150-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315219001945/0001493152-19-001945-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315220002406/0001493152-20-002406-index.htm
2018-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-08-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001171/0001567619-18-001171-index.htm
2018-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003916/0001567619-18-003916-index.htm
2018-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003919/0001567619-18-003919-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004374/0001567619-18-004374-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004376/0001567619-18-004376-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004378/0001567619-18-004378-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004380/0001567619-18-004380-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/0001628280-18-013909-index.htm
2020-01-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520000069/9999999995-20-000069-index.htm
2020-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520002943/9999999995-20-002943-index.htm
2020-07-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004141/9999999997-20-004141-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004563/9999999997-20-004563-index.htm

Arbutus Biopharma Corporation (ABUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-23Michael J. McElhaughChief Business OfficerSell20,000.005.01100,200.001,367,457.00https://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2018-08-13Michael J. SofiaChief Scientific OfficerSell4,250.009.5140,435.781,499,153.00https://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-11-28Mark J. MurrayDirectorBuy25,000.001.3533,750.00341,396.00https://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm